All In Biotech

Drug Trial Radar · NCT00407745

A 17-Week Trial To Assess Pregabalin For The Treatment Of Nerve Pain Due To Spinal Cord Injury

A 17-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Trial Of Pregabalin For The Treatment Of Chronic Central Neuropathic Pain After Spinal Cord Injury

Last checked: Nov 20, 2026Latest source record: Jan 25, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 220 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

220

Actual

Start

Jan 2007

Primary completion

Feb 2011

Study completion Feb 2011

Sponsor

Sponsor type
Industry
First posted
Dec 5, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate if pregabalin relieves nerve pain associated with spinal cord injury compared to placebo (pill that contains no active medicine). This study will also evaluate the safety of pregabalin in this patient population.

Conditions

  • Neuralgia
  • Spinal Cord Injuries

Interventions

  • placeboDrug

    Placebo

  • pregabalinDrug

    Pregabalin capsules taken twice daily up to 17 weeks (150-600 mg/day)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Duration Adjusted Average Change (DAAC) of Mean Pain ScoreTime frame: Baseline, Week 16

Locations

67 sites in 10 countries. Site status is shown where the registry gives one.

  • Pfizer Investigational Site

    Phoenix, Arizona

  • Pfizer Investigational Site

    Phoenix, Arizona

  • Pfizer Investigational Site

    Phoenix, Arizona

  • Pfizer Investigational Site

    Fresno, California

  • Pfizer Investigational Site

    Napa, California

  • Pfizer Investigational Site

    Northridge, California

  • Pfizer Investigational Site

    Pasadena, California

  • Pfizer Investigational Site

    Miami, Florida

  • Pfizer Investigational Site

    Miami, Florida

  • Pfizer Investigational Site

    Orlando, Florida

  • Pfizer Investigational Site

    Indianapolis, Indiana

  • Pfizer Investigational Site

    Overland Park, Kansas

  • Pfizer Investigational Site

    Detroit, Michigan

  • Pfizer Investigational Site

    New York, New York

  • Pfizer Investigational Site

    White Plains, New York

  • Pfizer Investigational Site

    Winston-Salem, North Carolina

  • Pfizer Investigational Site

    Bellevue, Ohio

  • Pfizer Investigational Site

    Johnstown, Pennsylvania

  • Pfizer Investigational Site

    Philadelphia, Pennsylvania

  • Pfizer Investigational Site

    Dallas, Texas

  • Pfizer Investigational Site

    Charleston, West Virginia

  • Pfizer Investigational Site

    Charleston, West Virginia

  • Pfizer Investigational Site

    Viña del Mar, Valparaiso, Chile

  • Pfizer Investigational Site

    Beijing, China

  • Pfizer Investigational Site

    Beijing, Beijing Municipality, China

  • Pfizer Investigational Site

    Chengdu, Sichuan, China

  • Pfizer Investigational Site

    Medellín, Antioquia, Colombia

  • Pfizer Investigational Site

    Brno, Czechia

  • Pfizer Investigational Site

    Liberec, Czechia

  • Pfizer Investigational Site

    Prague, Czechia

  • Pfizer Investigational Site

    Hong Kong, Hong Kong

  • Pfizer Investigational Site

    New Delhi, India

  • Pfizer Investigational Site

    Secunderabad, Andhra Pradesh, India

  • Pfizer Investigational Site

    Bangalore, Karnataka, India

  • Pfizer Investigational Site

    Bangalore, Karnataka, India

  • Pfizer Investigational Site

    Mangalore, Karnataka, India

  • Pfizer Investigational Site

    Lucknow, Uttar Pradesh, India

  • Pfizer Investigational Site

    Chiba, Japan

  • Pfizer Investigational Site

    Tokushima, Japan

  • Pfizer Investigational Site

    Yamagata, Japan

Showing 40 of 67 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.